Virtual Library

Start Your Search

Başak Oyan Uluç



Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey (ID 14012)

      16:45 - 18:00  |  Author(s): Başak Oyan Uluç

      • Abstract

      Background

      ALK mutation is observed in 4% of patients diagnosed with NSCLC. The present study aimed to evaluate the efficacy of crizotinib, an ALK inhibitor, and clinical characteristics of ALK-positive NSCLC patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      In this multicenter, retrospective study, data of ALK-positive advanced stage NSCLC patients who received crizotinib were retrieved from hospital records.

      4c3880bb027f159e801041b1021e88e8 Result

      Data of 353 ALK-positive metastatic NSCLC patients receiving crizotinib in any treatment line were analyzed. The mean age of the patients was 53.2±12.6 years [median, 53 years (21-85 years)] and 193 (54.7%) patients were male. Age at diagnosis was significantly higher in males than in females (54.8±11.8 years and 51.3±13.2 years, respectively; p=0.044). The rate of patients who never smoked was 50.1%. The most common histological subtype was adenocarcinoma (96%). The frequency of brain metastasis at the time of diagnosis was 23.4%. The most common initial symptoms were cough (56%) and dyspnea (53%). Initial ECOG score was 0 or 1 in 80% of the patients. Crizotinib had been used in 37% of the patients in the 1st-line treatment, in 45% of the patients in the 2nd-line treatment, and in 18% of the patients in the ≥3rd-line treatment.

      Table 1. Response rates of the patients

      Treatment line

      Overall
      N (%)

      1
      N (%)

      2
      N (%)

      3
      N (%)

      Other
      N (%)

      Complete response

      28 (7.9)

      9 (7.3)

      14 (8.9)

      4 (9.8)

      1 (5.6)

      Partial response

      217 (61.5)

      78 (62.9)

      103 (65.2)

      25 (61.0)

      10 (55.6)

      Stable disease

      50 (14.2)

      18 (14.5)

      21 (13.3)

      7 (17.1)

      4 (22.2)

      Progressive disease

      67 (13.3)

      19 (15.3)

      20 (12.7)

      5 (12.2)

      3 (16.7)

      Undefined

      11 (3.1)

      ORR

      245 (69.4)

      87 (70.2)

      117 (74.1)

      29 (70.8)

      11 (61.2)

      DCR

      295 (83.6)

      105 (84.7)

      138 (87.4)

      36 (87.1)

      7 (83.4)

      Undefined

      11 (3.1)

      ORR was 69.4% and DCR was 83.6% (Table 1). ORR and DCR in the patients received crizotinib were 70.2% and 84.7% in the 1st-line treatment, respectively and were 74.1% and 87.4% in the 2nd-line treatment, respectively. The frequency of brain metastasis was 40.2% at 12 months. Of these patients, the median PFS and OS were 11.3 and 28.0 months, respectively.

      The most common side effects were fatigue, visual disturbances, nausea, abdominal discomfort, and pretibial edema.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Clinical characteristics of ALK-positive patients and crizotinib efficacy are consistent with studies. Response rates and survival outcomes are similar regardless of treatment lines. Crizotinib is safely used in these patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53